Immedica Pharma Ab
Clinical trials sponsored by Immedica Pharma Ab, explained in plain language.
-
New hormone treatment shows promise for rare adrenal disorder
Disease control CompletedThis study looked at the long-term safety of a medication called Chronocort in 76 people aged 16 and older with congenital adrenal hyperplasia (CAH), a condition where the body can't make enough cortisol. Researchers monitored for signs of over- or under-treatment, adrenal crises…
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for babies with rare enzyme disorder: weekly shot shows promise
Disease control CompletedThis study tested a weekly injection of pegzilarginase (Loargys) in 3 infants under 24 months old with arginase 1 deficiency, a rare genetic disorder that causes harmful buildup of arginine. The goal was to see if the drug is safe and can lower arginine levels in the blood. The t…
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC